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Low back pain (LBP), defined as the localized pain or 
discomfort between the costal margins and superior gluteal 
line, with or without associated lower limb pain, is one of 
the most commonly encountered pain syndromes in adults. 
It is considered chronic LBP (CLBP), when pain persists for 
more than three months (1). CLBP might be disabling with 
increased missing hours of productive work or of personal 
activities and it can also be associated with significant excess 
of healthcare costs (2). Commonly, CLBP also gives rise to 
the genesis or exacerbation of various psychiatric disorders, 
such as depression and/or anxiety (3). 
Its clinical phenotype greatly varies depending on 
the underlying pathophysiology of the condition. On 
clinical grounds, CLBP can be categorized as this pain 
syndrome that (I) is associated with a specific underlying 
disease; (II) has prevalent the neuropathic component 
and; (III) is of mechanical origin being non-specific 
or without recognisable cause in the majority of cases. 
However, due to the complexity and heterogeneity of the 
condition, the diagnostic approach can be problematic, 
before the physician eventually is able to decide on the 
pathophysiology and source of CLBP origin (4). Besides 
this, there is currently lack of consensus regarding an 
objective measure or specific diagnostic criteria to accurately 
monitor its incidence and severity (5). 
CLBP often comprises both nociceptive and neuropathic 
components. It is urged that both of these components 
should be recognized and thoroughly treated separately 
in order to achieve a meaningful response to oral 
pharmacotherapies. However, clinical experience shows 
that the neuropathic component of CLBP, being the result 
of an underlying somatosensory lesion, remains often 
underdiagnosed and thus undertreated (5). The main reason 
to account for the latter fact is that patients who do not have 
the typical radicular presentation are often misdiagnosed as 
only having the nociceptive component of LBP. Recently 
it was demonstrated that appropriately use of behavioural 
evaluation and sensory examination led to successful 
differentiation between the nociceptive and neuropathic 
components in CLBP (6).
On the other hand, if the neuropathic component of 
LBP is successfully recognized, the use of neuropathic pain 
medications with antidepressants to target the serotonin-
noradrenaline system, e.g., duloxetine and/or antiepileptic 
drugs, e.g., gabapentin or pregabalin is often hampered 
by lack of clinically meaningful analgesia, by evidence of 
refractoriness or increased risk of adverse effects. Drug to 
drug interactions might also occur when combining oral 
pharmacological agents to target both the nociceptive 
and neuropathic components of CLBP (3). As such, its 
pharmacological therapy still remains an unmet need in 
clinical practice and further study is needed to identify a 
proper sensory phenotyping of CLBP patients to allow the 
development of more targeted therapies (3,7). 
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Taking into account the modest efficacy of systemic 
treatments and that CLBP is generated from the lumbar 
spine or its supporting structures, there is an increasing 
use over the last years of minimal invasive techniques to 
alleviate LBP, providing that the pain originates from 
single sources, including facet joint, disc, sacroiliac joint 
or a combination of these (8). There is evidence from 
uncontrolled trials that radiofrequency denervation is 
effective against CLBP, when strict selection criteria are 
adhered to establish the diagnosis and a specific procedure 
is applied (9,10). However, a recently published Cochrane 
review of 23 randomized clinical trials contradicts the 
latter findings, as it concludes for a modest effect of 
radiofrequency denervation on facet joint pain, mainly as a 
result of poor quality evidence of the studied procedures. 
Authors urged the need for high-quality RCTs with larger 
study samples to obtain enough statistical power, before 
one can with confidence conclude on the significance of 
radiofrequency denervation against CLBP (11). Moreover, 
the inconsistency in the improvement of sacroiliac and facet 
joint pain over time, as well as the absence of neurologic 
adverse events create relevant questions about if there is 
any robust pathophysiologic mechanism by which this 
intervention is acting. To be more specific: (I) why the effect 
of neurolysis is not sustained over time and; (II) why the 
injury of a nerve to block the transmission is not associated 
with significant rates of local neurological adverse events?
We read with great interest the recently published study 
by Juch et al. (12), in which authors presented the outcome 
of three pragmatic multicenter, nonblinded randomized 
clinical trials on the effectiveness of minimal interventional 
treatments in Dutch participants with CLBP. These studies, 
coined as the “The Mint Randomized Clinical Trials” were 
conducted to provide evidence of higher quality on the 
topic by overcoming the limitations of previous publications 
as these were delineated in the Cochrane review (11). To 
achieve that objective, authors delivered radiofrequency 
denervation, added to a standardized exercise program 
(intervention arm) vs. physiotherapy alone (control arm) 
on an adequate number of unresponsive to conservative 
care CLBP patients. Participants had a single positive 
diagnostic block at the facet joints (n=251 participants), 
sacroiliac joints (n=228 participants), or a combination of 
facet joints, sacroiliac joints, or intervertebral disks (n=202 
participants). It was required per protocol a decrease of 
at least two points in the numeric pain scale (NPS; range, 
0–10) measured three months after the once-delivered 
intervention to score for meaningful clinical analgesia. 
The mean baseline pain intensity of participants was 7.1, 
according to NPS. A total of 344 patients was allocated to 
the intervention arm and 337 were used to serve as controls. 
The demographics were comparable between arms, whereas 
the majority of participants (n=599; 88%) completed the 
study, being able to present in the predetermined 3-month 
after procedure follow up visit. Only the long-term follow-
up of the sacroiliac trial can be assumed as underpowered 
due to the significant number of patients lost, mainly 
in the non-interventional arm. Notably, the combined 
trial has almost 30% of patients who failed to complete 
the exercise treatment in the non-interventional arm. 
Nevertheless, the analysis of data all together highlighted 
an insignificant mean difference in pain intensity between 
the radiofrequency denervation and control groups at 
3 months, independently if the procedure was delivered in 
the facet joints, sacroiliac joints or combined. Taking into 
account the several limitations in their work, including 
among others the unblinded study design; the absence of 
placebo; the lack of reference standard for diagnosing facet 
or sacroiliac joint pain as well as the lack of correctional 
adjustments for multiple comparisons, the authors provided 
evidence for a low efficacy of radiofrequency denervation in 
CBLP patients, thus advising against its use (12). Normally, 
the applied nonblinded study design would have been 
against the treatment arm if the intervention was really 
effective; but in the current case, one can claim that it 
only reinforces the results of this negative study. Likewise, 
considering that placebo can improve up to 30% of pain 
perception, the lack of sham or fake radiofrequencies use 
as a placebo intervention in the current setting (12) further 
reinforces, in our opinion, the negative results.
Several questions arose from the results reported by 
Juch et al. (12); the majority of those have been openly 
expressed in three letters to the editor (13) sent by other 
groups to criticize numerous methodological aspects of 
the “Mint Trials”. The main facets of criticism included: 
(I) authors employed less stringent diagnostic criteria to 
select patients for delivering radiofrequency denervation, 
compared to the Spine Intervention Society guidelines. 
This was deemed inappropriate as it may confine significant 
bias resulting in high false-positive rates (25–45%) of CLBP 
diagnosis (14).  Juch et al .  (12),  acknowledged the 
significance of this issue and proceeded to online 
corrections of references (13), although it is difficult for 
us to comprehend the real meaning of this action, because 
references might have been changed but the definition used 
as a diagnostic criterion is impossible to correct at a second 
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stage and thus remained the same; (II) it was also claimed 
that the use of a small gauge diameter electrode decreased 
the possibility of adequate neurolysis, thus resulting in 
significant technical bias underpinning the likelihood of 
false-negative outcome after the intervention. Juch et al. (12), 
acknowledged that the needle size, its placement and other 
procedure’s parameters might vary in different countries and 
settings where the procedure is performed with the much 
larger 18-gauge diameter electrodes. However, as they state, 
the use in their setting of a small gauge diameter electrode 
(22G) was in keeping with the national Dutch standards and 
was also evidence-based; (III) the use of mean pain intensity, 
graded by a numeric rating scale, as the primary endpoint 
was also disputed and was suggested that the latter together 
with the definition of procedure’s efficacy at the low value of 
30% reduction of pain, might have also been potent factors 
enhancing bias. Juch et al. (12), proved with the use of post-
hoc analyses that there was no evidence of bias from the 
method they applied.  
Finally, the most important criticism was probably 
about the applied method to diagnose facet pain with the 
use of single and not double positive diagnostic facet me-
dial branch block prior to radiofrequency denervation. 
As acknowledged by the authors (12), to apply a single 
block could indeed result in lower diagnostic specificity 
and increased false-positive rates, but this approach was 
in keeping with national Dutch practice and the threshold 
of pain reduction of at least 50% (positive response) after 
a single block is most commonly applied for research 
purposes. However, one cannot disregard that the false-
positive diagnostic rate of performing single rather than 
double blocks can be up to 45% (15). 
Nevertheless, in our opinion the study by Juch et al. (12) 
is of significance, because it is presenting for the first time 
the summary outcome of three randomized controlled, 
sufficiently powered, in pragmatic conditions, trials, on the 
efficacy of radiofrequency denervation to alleviate CLBP. 
This study clearly concluded negatively on the clinically 
meaningful analgesia of the intervention. 
However, taking into account the above-mentioned 
constructive debate on the topic, as also recent controversial 
evidence from other groups demonstrating a significant 
and long-lasting pain relief after delivering radiofrequency 
denervation in appropriately selected patients (16), further 
studies with improved study design and procedures, than 
that applied by Juch et al. (12), are warranted. Bearing 
the current evidence in mind, there is an obvious need of 
future studies to overcome all the current methodological 
limitations so as to eventually shed light on the real 
analgesic effect of minimally-invasive radiofrequency 
denervation among patients with CLBP. 
As a closing remark, we can say that CLBP possess a 
quite generic definition, including many different causes 
and mechanisms. As such, it is necessary to establish its 
better definition beyond topographical regions, and a more 
analytic delimitation of the underlying causes to improve 
the therapeutic approaches. We would also like to encourage 
search for any objective neurophysiological measure to 
avoid the present controversy on the topic. Towards this 
view, further studies applying quantitative sensory testing of 
C fibers in corresponding spinal dermatomes or technically 
adapted microneurography recordings from CLBP patients, 
are warranted to test if there is any real neurophysiological 
background to recommend this intervention. Finally, 
researchers on the topic should reach to a consensus 
regarding the diagnostic criteria that are to be used in future 
studies. Given the current lack of effective pharmacological 
analgesics to treat this commonly encountered pain 
syndrome, the dispel of any doubts on this specific topic is 
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